Investigational drug · Phase 2
SYH2051
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumors, Breast Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "SYH2051"
First trial start
2025
Mar 20, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYH2051", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors
- Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SYH2051" as an intervention, largest first.
- Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid TumorsPivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT06775236 · 410 participants (planned) · Start Mar 20, 2025 · Primary completion Jun 15, 2027
Drug: SYS6010 jnjection; monotherapy chemotherapy and 1 more · For: Advanced Solid Tumors; Breast Cancer
- A Study of SYH2051 in Combination With Irinotecan Hydrochloride Liposome Injection in Subjects With Advanced Solid TumorsNot yet recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT07911579 · 154 participants (planned) · Start Nov 30, 2026 · Primary completion Dec 30, 2028
Drug: SYH2051; Irinotecan Hydrochloride Liposome. · For: Advanced Solid Tumors
Sites: Tianjin, China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT06011291 · 73 participants (planned) · Start Aug 15, 2023 · Primary completion Dec 31, 2024
Drug: SYH2051 tablets · For: Solid Tumors; Head and Neck Cancer
Sites: Shijiazhuang, China
- A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal TumorsActive, not recruiting
Fujian Cancer HospitalGovernment (non-federal)
NCT07104877 · 25 participants · Start Apr 18, 2024 · Primary completion Nov 1, 2024
Drug: SYS6010; SYH2051 · For: Colorectal Cancer; Gastric Cancer (GC); Gastrointestinal Tumors
Sites: Fuzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Targeting ATM Kinase in Cancer-A Comprehensive Review.
Kciuk M, Machura G, Wanke K, et al. · Oncol Res 2026
- ATM inhibitors in cancer radiotherapy: Mechanisms, clinical development, and future directions.
Al-Zoubi RM, Garada K, Al Huneidi R, et al. · Eur J Med Chem 2025
- Small Molecular Inhibitors That Target ATM for Drug Discovery: Current Research and Potential Prospective.
Qian C, Li X, Zhang J, et al. · J Med Chem 2024
Also in development for Advanced Solid Tumors
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.